Novartis AG ADR (NVS)vsSenseonics Holdings, Inc. Common Stock (SENS)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
SENS
Senseonics Holdings, Inc. Common Stock
$6.67
-4.85%
HEALTHCARE · Cap: $357.07M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 160373% more annual revenue ($56.58B vs $35.26M). NVS leads profitability with a 23.9% profit margin vs -196.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
SENS
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for SENS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 71.8% year-over-year
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Trading at 8.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SENS
The strongest argument for SENS centers on Revenue Growth. Revenue growth of 71.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SENS
The primary concerns for SENS are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while SENS is a hypergrowth play — different risk/reward profiles.
SENS carries more volatility with a beta of 1.06 — expect wider price swings.
SENS is growing revenue faster at 71.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 24/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Senseonics Holdings, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Senseonics Holdings, Inc., a medical technology company, develops and markets continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company is headquartered in Germantown, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?